Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States

References

• Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus–attributable cancers — United States, 2012–2016. Centers Dis Control Prev. 2019;68(33):724–28.
   Google Scholar
• McClung NM, Gargano JW, Park IU. Estimated number of cases of high-grade cervical lesions diagnosed among women — United States, 2008 and 2016. Centers Dis Control Prev. 2019;68:337–43.
   Google Scholar
• Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014. Am J Public Health. 2018;108:112–19.
   PubMed Web of Science ®Google Scholar
• Sudenga SL, Nyitray AG, Torres BN, Silva R, Villa L, Lazcano-Ponce E, Abrahamsen M, Baggio ML, Salmeron J, Quiterio M, et al. Comparison of anal HPV natural history among men by country of residence: Brazil, Mexico, and the United States. J Infect. 2017;75(1):35–47. doi:10.1016/j.jinf.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Liu G, Markowitz LE, Hariri S, Panicker G, Unger ER. Seroprevalence of 9 human papillomavirus types in the United States, 2005–2006. J Infect Dis. 2016;213(2):191–98. doi:10.1093/infdis/jiv403.
   PubMed Web of Science ®Google Scholar
• Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, Radley D, Vuocolo S, Haupt RM, Saah A, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of gardasil™ in adult women. PLOS One. 2013;8(12):e83431. doi:10.1371/journal.pone.0083431.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37. doi:10.1038/bjc.2011.185.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57. doi:10.1016/S0140-6736(09)60691-7.
   PubMed Web of Science ®Google Scholar
• Joura E, Vandermeulen C, Peters K, Perino A, Ulied A, Seppä I, Jotterand V, Cheon K, Rawat S, Luxembourg A, et al., Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared with young women 16-26 years of age: an open-label phase 3 trial. in EUROGIN International Multidisciplinary HPV Congress, Monaco. 2019.
   Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves expanded use of gardasil 9 to include individuals 27 through 45 years old. Washington, D.C.: FDA News Release; 2018.
   Google Scholar
• Centers for Disease Control and Prevention. HPV Vaccine recommendations. 2016. 13/12/2018. [accessed 2018 Dec 13]. Available from: https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html.
   Google Scholar
• Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702. doi:10.15585/mmwr.mm6832a3.
   PubMed Web of Science ®Google Scholar
• Chesson H. Overview of health economic models for HPV vaccination of mid-adults, C.f.D.C.a. Prevention, Editor. Atlanta, GA; 2019.
   Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28–41. doi:10.3201/eid1301.060438.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–67. doi:10.1016/j.vaccine.2010.08.030.
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. CPI-All Urban Consumers (Current Series) - Medical care in U.S. city average, all urban consumers, not seasonally adjusted. 2018. [accessed 2018 April]. https://data.bls.gov/pdq/SurveyOutputServlet.
   Google Scholar
• Garnett GP, Anderson RM. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci. 1993;342:137–59.
   PubMed Web of Science ®Google Scholar
• Garnett GP, Anderson RM. Balancing sexual partnership in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J Math Appl Med Biol. 1994;11(3):161–92. doi:10.1093/imammb/11.3.161.
   PubMedGoogle Scholar
• Walker TY, Elam-Evans LD, Yankey D. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2018. Centers Dis Control Prev. 2019;68:718–23.
   Google Scholar
• Chesson HW, Meites E, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. Vaccine. 2018;36(29):4362–68. doi:10.1016/j.vaccine.2018.04.071.
   PubMed Web of Science ®Google Scholar
• Lewis RM, Markowitz LE. Human papillomavirus vaccination coverage among females and males, national health and nutrition examination survey, United States, 2007–2016. Vaccine. 2018;36(19):2567–73. doi:10.1016/j.vaccine.2018.03.083.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunization. Statement on HPV vaccination. UK. GOV;2018.
   Google Scholar
• Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. Circulation. 2014;129(22):2329–45. doi:10.1161/CIR.0000000000000042.
   PubMed Web of Science ®Google Scholar
• Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily M-C, Smith MA, Berkhof J, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Glob Health. 2016;1(1):e8–e17. doi:10.1016/S2468-2667(16)30001-9.
   Web of Science ®Google Scholar
• Laprise J-F, Chesson HW, Markowitz LE, Drolet M, Martin D, Bénard É, Brisson M. Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med. 2020;172(1):22–29. doi:10.7326/M19-1182.
   PubMed Web of Science ®Google Scholar
• Burger EA, de Kok Imcm, Groene E, Killen J, Canfell K, Kulasingam S, Kuntz KM, Matthijsse S, Regan C, Simms K, et al. Estimating the natural history of cervical carcinogenesis using simulation models: A CISNET comparative analysis. J Natl Cancer Inst; 2020;112(9):955–963.
   PubMedGoogle Scholar
• Harper CR, Dittus PJ, Leichliter JS, Aral SO. Changes in the distribution of sex partners in the United States: 2002 to 2011-2013. Sex Transm Dis. 2017;390(10108):96–100. doi:10.1097/OLQ.0000000000000554.
   Web of Science ®Google Scholar
• Ryser MD, Rositch A, Gravitt PE. Modeling of US Human Papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution. J Infect Dis. 2017;216(5):604–11. doi:10.1093/infdis/jix333.
   PubMed Web of Science ®Google Scholar
• Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010;70(21):8569–77. doi:10.1158/0008-5472.CAN-10-0621.
   PubMed Web of Science ®Google Scholar
• Merck & Co. Data on file. 2020.
   Google Scholar
• Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Munoz A. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12):2077–87. doi:10.1086/425907.
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA. Incident detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25–65 years. J Infect Dis. 2016;214(5):665–75. doi:10.1093/infdis/jiw074.
   PubMed Web of Science ®Google Scholar
• Shvetsov YB, Hernandez B, McDuffie K, Wilkens L, Zhu X, Ning L, Killeen J, Kamemoto L, Goodman M. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis. 2009;48(5):536–46. doi:10.1086/596758.
   PubMed Web of Science ®Google Scholar
• Goodman MT, Shvetsov Y, McDuffie K, Wilkens L, Zhu X, Thompson P, Ning L, Killeen J, Kamemoto L, Hernandez B, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis. 2010;201(9):1331–39. doi:10.1086/651620.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Rowena Del Rosario-Raymundo M, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138(10):2428–38. doi:10.1002/ijc.29971.
   PubMed Web of Science ®Google Scholar
• Gargano JW, Zhou F, Stokley S, Markowitz LE. Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014. Vaccine. 2018;36(23):3381–86. doi:10.1016/j.vaccine.2018.03.045.
   PubMed Web of Science ®Google Scholar
• Gopalappa C, Farnham PG, Chen YH, Sansom SL. Progression and transmission of HIV/AIDS (PATH 2.0): a new. Agent-Based Model to Estimate HIV Transmissions in the United States. Med Decis Making. 2016;37(2):224–33.
   Google Scholar
• Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28(24):4091–102. doi:10.1016/j.vaccine.2009.09.125.
   PubMed Web of Science ®Google Scholar
• Merck. Data on file. 2009.
   Google Scholar
• Dyne EAV, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus–associated cancers — United States, 1999–2015. MMWR. 2018;67(33):918–24.
   Web of Science ®Google Scholar
• German RR, Fink AK, Heron M, Stewart SL, Johnson CJ, Finch JL, Yin D. The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol. 2011;35(2):126–31. doi:10.1016/j.canep.2010.09.005.
   PubMed Web of Science ®Google Scholar
• Kleina RF, Sperga I, Lutinska MD. The analysis of undiagnosed malignancies. Pap Anthropol. 2011;20:199–208.
   Google Scholar
• Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology. 2005;47(6):551–59. doi:10.1111/j.1365-2559.2005.02243.x.
   PubMed Web of Science ®Google Scholar
• Mieno MN, Tanaka N, Arai T, Kawahara T, Kuchiba A, Ishikawa S, Sawabe M. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. J Epidemiol. 2016;26(4):191–98. doi:10.2188/jea.JE20150010.
   PubMed Web of Science ®Google Scholar